In this presentation, Dr. Richard Johnson explored why obesity and related conditions such as diabetes, hypertension, and Alzheimer’s have surged since the late 19th century. He argues that traditional calorie-centric views overlook the deeper evolutionary and biochemical drivers of these diseases. Drawing on animal studies and historical trends, he shows how humans, like hibernating bears or migrating birds, are wired to store fat in response to environmental cues. In nature, fructose signals animals to overeat and conserve energy before periods of scarcity, but in today’s world of constant sugar availability—especially from processed foods and high-fructose corn syrup—this ancient survival mechanism has become maladaptive.
Johnson explained how excess fructose disrupts energy regulation by inducing leptin resistance, lowering cellular ATP, and increasing uric acid, which promotes oxidative stress and mitochondrial dysfunction. These processes trigger weight gain, insulin resistance, and fat accumulation in organs, linking dietary sugars to obesity, diabetes, cardiovascular disease, and even neurodegeneration. He emphasizes that obesity is not simply about eating too many calories but about how certain nutrients hijack biological pathways. To reverse the epidemic, Johnson advocates reducing refined sugar intake, moderating fructose consumption, improving carbohydrate quality, supporting mitochondrial health through lifestyle strategies, and addressing uric acid levels—shifting the focus from calorie counting to targeting the metabolic roots of modern disease.
This BSI Medical Society Webinar was streamed on August 12th, 2025.
A 10-minute summary of the webinar is available here free, for anyone, while the full video is available for Medical Society Members and MetFix affiliates in their dashboard.
Let's start with the truth!
Support the Broken Science Initiative.
Subscribe today →
recent posts
Metabolic health, medical education, and the case for bringing clinicians and coaches together
At the 2026 Unbreakable Health Retreat in Miami, Emily Kaplan hosted a panel with Bob Kaplan, Professor Thomas Seyfried, and Dr. Derek Lee on what it means to treat cancer as a metabolic disease. They discussed the glucose-ketone index (GKI), nutritional ketosis, and strategies aimed at restricting the fuels cancer cells depend on while considering how metabolic therapy can fit alongside standard cancer treatment.
The conversation also addressed the practical realities patients face when trying to pursue a metabolic approach within the conventional oncology system, including questions about nutrition, repurposed drugs, inherited cancer risk, and how to evaluate different treatment options. Seyfried and Lee connected these clinical questions back to mitochondrial dysfunction, fermentation, and the metabolic vulnerabilities that may offer additional targets for cancer treatment.
An abbreviated version of this discussion is available here, for free.
At the 2026 Unbreakable Health Retreat in Miami, Professor Thomas Seyfried presented the case that cancer is fundamentally a mitochondrial metabolic disease rather than primarily a genetic one. He contrasts the dominant somatic mutation theory with a metabolic model in which impaired mitochondrial respiration drives a shift toward fermentation, dysregulated cell growth, and the mutations commonly associated with cancer.
Citing the work of Otto Warburg and research from his lab at Boston College, Seyfried explains how cancer cells rely heavily on fermentable fuels—particularly glucose and glutamine—and why mitochondrial dysfunction sits upstream of many of the genetic abnormalities seen in tumors. He also discusses reactive oxygen species, altered cellular signaling, and the role of mitochondria in regulating cell growth and behavior.
The presentation then turns to the therapeutic implications of this model. Seyfried explains strategies aimed at placing tumor cells under metabolic stress by restricting the fuels they depend on, including ketogenic metabolic therapy and approaches targeting glucose and glutamine. For Seyfried, the therapeutic target follows directly from the biology: restrict the fuels cancer cells depend on, exploit their metabolic weaknesses, and treat mitochondrial dysfunction as the central feature of the disease.
An abbreviated version of this discussion is available here, for free.
MetFix and BSI Members can view the full 54-minute video.
